Status:

WITHDRAWN

The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients

Lead Sponsor:

University Hospital, Basel, Switzerland

Conditions:

Primary Open Angle Glaucoma

Eligibility:

All Genders

18-65 years

Brief Summary

To quantify oxidative stress in circulating leukocytes of normal tension glaucoma patients, prior to and one month after routine vascular therapy.

Detailed Description

There are two accepted medical modalities for glaucoma treatment. The first, is a local application of an intraocular pressure (IOP) lowering drug. The second, is the application of systemic drugs to ...

Eligibility Criteria

Inclusion

  • For NTG patients:
  • A mean untreated intraocular pressure consistently equal to or below 21mmHg or median intraocular pressure equal to or below 20mmHg on diurnal testing (at least three measurements) with no single measurement greater than 24mmHg
  • Open drainage angles on gonioscopy
  • Typical optic disc damage with glaucomatous cupping and thinning of neuroretinal rim
  • Visual field defect congruent to glaucomatous disc alteration
  • No other pathological findings upon slit-lamp examination and indirect fundoscopy
  • Vasospastic propensity will be assumed if a clear history of frequent cold hands (answering yes to the questions:" Do you always have cold hands, even during the summer time?" and "Do other people tell you that you have cold hands?") is reported.
  • For healthy subjects:
  • An intraocular pressure \< 20 mmHg
  • No history of ocular or systemic disease
  • No history of chronic or current systemic or topical medication, or of drug or alcohol abuse
  • Normal blood pressure (100-140/60-90mm Hg)
  • Best corrected visual acuity above 20/32 in both eyes
  • No pathological findings upon slit-lamp examination and indirect fundoscopy

Exclusion

  • EXCLUSION CRITERIA:
  • Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
  • Pigmentary dispersion or pseudoexfoliation
  • Evidence for any secondary cause for a glaucomatous optic neuropathy (trauma, steroids, uveitis)
  • History of chronic or recurrent severe inflammatory eye disease (eg. scleritis, uveitis) or clinically significant or progressive retinal disease (eg. diabetic retinopathy)
  • History of ocular trauma or intraocular surgery within the past 6 months
  • History of systemic infection or inflammation within the past 3 months
  • Need for any concomitant medications that may interfere with the evaluation of leukocytes (eg: steroids, immunosuppressives)
  • Patients with a significant history and /or active alcohol or drug abuse (significant is defined as that which may influence results of the study)

Key Trial Info

Start Date :

June 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2010

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00465348

Start Date

June 1 2009

End Date

June 1 2010

Last Update

October 25 2012

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.